American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Selinexor in Combination with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM

ASH 2020 – Multiple Myeloma

Interim results from the STOMP study show that the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates and encouraging progression-free survival in heavily pretreated patients with multiple myeloma. Read More ›

Ciltacabtagene Autoleucel Is a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM

ASH 2020 – Multiple Myeloma

The preliminary results of the phase 1b/2 CARTITUDE-1 study revealed that early, deep, and durable responses were demonstrated and that a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM was observed. Read More ›

AMG 701, a Bispecific T-Cell Engager Molecule, in RRMM: A Phase 1 First-in-Human Study

ASH 2020 – Multiple Myeloma

Results from a first-in-human study of AMG 701, an anti-BCMA BiTE molecule, showed an acceptable safety profile, promising efficacy, and a favorable pharmacokinetic profile in heavily pretreated patients with RRMM, thereby supporting ongoing evaluation. Read More ›

Open-Label, Phase 1b/2, Dose-Escalation Study of a Novel Agent in Patients with RRMM (STOMP)

ASH 2020 – Multiple Myeloma

The combination of selinexor, pomalidomide, and dexamethasone is efficacious, durable and safe in patients with RRMM. Read More ›

Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM

ASH 2020 – Multiple Myeloma

Adding daratumumab to lenalidomide, bortezomib, and dexamethasone induction and consolidation, followed by maintenance with lenalidomide ± daratumumab for transplant-eligible patients with NDMM elicits deep and improving responses, with no additional safety concerns upon longer follow-up. Read More ›

Isatuximab for Patients with Previously Treated AL Amyloidosis

ASH 2020 – Multiple Myeloma

Results from a phase 2 study of isatuximab in previously treated patients with amyloid light-chain (AL) amyloidosis showed encouraging efficacy and a good safety profile. Read More ›

A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM

ASH 2020 – Multiple Myeloma

Although promising efficacy and acceptable toxicity were reported for belantamab mafodotin + pomalidomide + dexamethasone in patients with RRMM, the high rate of dose holds at the 2.5-mg/kg level warranted examination of alternative dosing schedules. Read More ›

APOLLO: Combination of Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM

ASH 2020 – Multiple Myeloma

Daratumumab + pomalidomide and dexamethasone reduced the risk for disease progression and death without additional safety signals versus pomalidomide and dexamethasone alone for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor. Read More ›

ANCHOR: Melflufen plus Dexamethasone and Daratumumab or Bortezomib in RRMM Refractory to an Immunomodulatory Drug and/or a Proteasome Inhibitor

ASH 2020 – Multiple Myeloma

The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated. Read More ›

VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM

ASH 2020 – Multiple Myeloma

Consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance proved superior to lenalidomide maintenance alone in progression-free survival and myeloma response among transplant-eligible patients with NDMM. Read More ›

American Society of Hematology (ASH)

Page 13 of 44